Capital Fund Management (CFM)
PETX

Capital Fund Management (CFM)’s Aratana Therapeutics, Inc. PETX Stock Holding History

Capital Fund Management (CFM)’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-47,648
Closed -$344K – 1842
2017
Q2 		$344K Sell
47,648
-5,500
-10% -$33.8K ﹤0.01% 1228
2017
Q1 		$282K Buy
+53,148
New +$359K ﹤0.01% 1312
2016
Q4 		– Sell
-47,000
Closed -$440K – 1947
2016
Q3 		$440K Buy
+47,000
New +$390K ﹤0.01% 1256

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Capital Fund Management (CFM)'s PETX Position: Q3 2017 in Review

Capital Fund Management (CFM) sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2017, closing a stake of 47,648 shares — an estimated $344K sold.

Capital Fund Management (CFM) first reported a position in PETX in Q3 2016 and held it in 3 quarters. The position peaked at $440K in Q3 2016. 96 funds tracked by Wall St. Rank hold PETX as of Q3 2017.

  • Capital Fund Management (CFM) reported no remaining Aratana Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 47,648 Aratana Therapeutics, Inc. shares in Q3 2017, an estimated $344K.
  • Capital Fund Management (CFM) first reported a position in Aratana Therapeutics, Inc. in Q3 2016 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Aratana Therapeutics, Inc. position peaked at $440K in Q3 2016.
  • 96 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2017.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2017, filed 13 Nov 2017.